MP04-06 POLYMORPHISMS OF NOS3 G894T ARE ASSOCIATED WITH RESPONSIVENESS TO DOXAZOSIN IN BPH/LUTS

Abstract

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Epidemiology & Evaluation1 Apr 2018MP04-06 POLYMORPHISMS OF NOS3 G894T ARE ASSOCIATED WITH RESPONSIVENESS TO DOXAZOSIN IN BPH/LUTS Yung-Chin Lee, Chia-Chu Liu, and Shu-Pin Huang Huang Yung-Chin LeeYung-Chin Lee More articles by this author , Chia-Chu LiuChia-Chu Liu More articles by this author , and Shu-Pin Huang HuangShu-Pin Huang Huang More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.156AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Nitric oxide (NO) has recently gained increasing recognition as an important neurotransmitter of functions in the lower urinary tract. This prospective study firstly investigated the association of eNOS G894T gene polymorphism with the responsiveness to a1-blocker in men with benign prostatic hyperplasia related lower urinary tract symptoms (BPH/LUTS). METHODS 136 patients with BPH/LUTS were recruited from urology outpatient clinics in a university hospital. Oral therapy with doxazosin- GITS 4 mg once-daily was given for 12 weeks. The drug efficacy was assessed by the changes from baseline in the total International Prostate Symptom Score (IPSS), maximum urinary flow rate (Qmax) and post-void residual urine volume (PVR) at 12 weeks of treatment. The responders to doxazosin GITS were defined as those who had a total IPSS decrease of more than 4 points from baseline. The eNOS G894T polymorphisms were determined using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. RESULTS Patients had statistically significant improvements in total IPSS, QoL and Qmax (P<0.01) for a 12-week period of treatment. Using multiple logistic regression analysis adjusted for age and IPSS, our results showed that eNOS 894T allele carrier was an independent factor for drug non-responder (p=0.03, OR=4.19). Besides, the decreased responder rate (p=0.01), as well as the lower improvements of IPSS (p=0.02) and Qmax (p=0.03), were significantly associated with an increment of the T allele number. CONCLUSIONS The presence of eNOS 894T allele had a significantly negative impact on responsiveness to a1-blocker in BPH/LUTS treatment, suggesting that eNOS G894T gene polymorphisms may play an implication as a genetic susceptibility factor for drug efficacy in men with BPH/LUTS. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e34 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Yung-Chin Lee More articles by this author Chia-Chu Liu More articles by this author Shu-Pin Huang Huang More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...